LIFE LINCO-SPEC 667MG SOLUBLE POWDER

Maa: Malesia

Kieli: englanti

Lähde: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Aktiivinen ainesosa:

Lincomycin Hydrochloride (monohydrate); Spectinomycin Sulfate (tetrahydrate)

Saatavilla:

Life Biopharma Sdn. Bhd.

INN (Kansainvälinen yleisnimi):

Lincomycin Hydrochloride (monohydrate); Spectinomycin Sulfate (tetrahydrate)

Kpl paketissa:

150 gm; 300 gm; 600 gm; 900 gm

Valmistaja:

Life Biopharma Sdn. Bhd.

Pakkausseloste

1
FOR ANIMAL USE ONLY
Brand or Product Name :
LIFE LINCO-SPEC 667MG SOLUBLE POWDER
Name and Strength of Active Substance(s)
Each gram of LIFE LINCO-SPEC 667MG SOLUBLE POWDER contains Lincomycin
222 mg (equivalent to Lincomycin Hydrochloride 251.74 mg) and
Spectinomycin 445 mg (equivalent to Spectinomycin
Sulfate Tetrahydrate 672.81 mg).
Product Description
LIFE LINCO-SPEC 667MG SOLUBLE POWDER is a white or off-white powder
for use in drinking water.
Target Species
Chickens and pigs.
Pharmacology Properties
LIFE LINCO-SPEC 667MG SOLUBLE POWDER contains the antibiotics
lincomycin and spectinomycin, having a complementary spectrum of
activity.
Lincomycin
Lincomycin is a lincosamide antibiotic derived from Streptomyces
lincolnensis which inhibits protein synthesis. Lincomycin binds to the
50S sub-unit of the bacterial ribosome close to the peptidyl transfer
centre and interferes with the peptide chain elongation process by
inhibiting the formation of the 50S sub-unit and by stimulating
ribosomal peptidyl-tRNA dissociation. Lincomycin is active against
gram-
positive bacteria, some anaerobic gram-negative bacteria (such as
Brachyspira hyodysenteriae) and mycoplasmas. It has little or no
action against gram-negative bacteria such as Escherichia coli.
While the lincosamides are generally considered to be bacteriostatic
agents, the activity is depending on the sensitivity of the organism
and concentration of the antibiotic. Lincomycin may be either
bactericidal or bacteriostatic. Resistance to lincomycin is frequently
conferred by plasmid-borne factors (erm genes) coding for methylases
modifying the ribosomal binding site and frequently leading to cross-
resistance to other antimicrobials of the MLSb group. However, the
most prevalent mechanism in B. hyodysenteriae and mycoplasmas is the
alteration of the binding site through mutational events
(chromosomal resistance). Lincomycin resistance mediated by efflux
pumps, or by inactivating enzymes, has also been described. There is
often complete cross-resistance between linc

Valmisteyhteenveto

1
FOR ANIMAL USE ONLY
Brand or Product Name :
LIFE LINCO-SPEC 667MG SOLUBLE POWDER
Name and Strength of Active Substance(s)
Each gram of LIFE LINCO-SPEC 667MG SOLUBLE POWDER contains Lincomycin
222 mg (equivalent to Lincomycin Hydrochloride 251.74 mg) and
Spectinomycin 445 mg (equivalent to Spectinomycin
Sulfate Tetrahydrate 672.81 mg).
Product Description
LIFE LINCO-SPEC 667MG SOLUBLE POWDER is a white or off-white powder
for use in drinking water.
Target Species
Chickens and pigs.
Pharmacology Properties
LIFE LINCO-SPEC 667MG SOLUBLE POWDER contains the antibiotics
lincomycin and spectinomycin, having a complementary spectrum of
activity.
Lincomycin
Lincomycin is a lincosamide antibiotic derived from Streptomyces
lincolnensis which inhibits protein synthesis. Lincomycin binds to the
50S sub-unit of the bacterial ribosome close to the peptidyl transfer
centre and interferes with the peptide chain elongation process by
inhibiting the formation of the 50S sub-unit and by stimulating
ribosomal peptidyl-tRNA dissociation. Lincomycin is active against
gram-
positive bacteria, some anaerobic gram-negative bacteria (such as
Brachyspira hyodysenteriae) and mycoplasmas. It has little or no
action against gram-negative bacteria such as Escherichia coli.
While the lincosamides are generally considered to be bacteriostatic
agents, the activity is depending on the sensitivity of the organism
and concentration of the antibiotic. Lincomycin may be either
bactericidal or bacteriostatic. Resistance to lincomycin is frequently
conferred by plasmid-borne factors (erm genes) coding for methylases
modifying the ribosomal binding site and frequently leading to cross-
resistance to other antimicrobials of the MLSb group. However, the
most prevalent mechanism in B. hyodysenteriae and mycoplasmas is the
alteration of the binding site through mutational events
(chromosomal resistance). Lincomycin resistance mediated by efflux
pumps, or by inactivating enzymes, has also been described. There is
often complete cross-resistance between linc